CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 36 enrolled
Drug / intervention
acitretindrug
Likely dose
acitretin 0.3 mg/Kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00723437
NCT00723437Phase 4Completed
CompareCT.gov

Evaluation of Nail Psoriasis Severity Index (NAPSI) and Modified Napsi in Patients With Nail Psoriasis Treated With Acitretin

Istituti Fisioterapici Ospitalieri·interventional·Posted Jul 28, 2008·Updated Jul 28, 2008

In Brief

A Phase 4 clinical trial evaluating acitretin for Psoriasis. Completed, enrolled 36 participants across 1 site.

Detailed Summary

Objective: Efficacy of systemic retinoid therapy of nail psoriasis has never been assessed objectively. Evaluate therapeutic efficacy of acitretin in patients with isolated nail psoriasis. Design: Open-study on thirty-six patients with moderate to severe nail psoriasis treated with acitretin. Participants: Patients included 27 men and 9 women (mean age 41) with nail psoriasis. Intervention: Therapy consisted of acitretin 0.2 to 0.3 mg/Kg/day for 6 months. Main Outcome Measure(s): Clinical evaluation, NAPSI and modified NAPSI scores before therapy, every 2 months during therapy and 6 months after treatment.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPsoriasis
CountriesItaly
CollaboratorsUniversity of Bologna

Timeline

Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedJul 28, 2008
Enrollment StartJan 1, 2005
Primary CompletionJan 1, 2007
Study CompletionJul 1, 2008
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 17.9 years ago

Interventions

acitretindrug

Acitretin at the dosage of 0.2 to 0.3 mg/Kg/day for 6 months.